The potential impact of human papillomavirus vaccination in contemporary cytologically screened populations may be underestimated: An observational retrospective analysis of invasive cervical cancers

International Journal of Cancer

Volumn 125, Issue 10, 2009, Pages 2425-2427

  Powell, Ned ^a   Boyde, Adam ^b   Tristram, Amanda ^a   Hibbitts, Sam ^a   Fiander, Alison ^a  

^a CARDIFF UNIVERSITY   (United Kingdom)

^b UNIVERSITY HOSPITAL OF WALES   (United Kingdom)

Author keywords

Cervical cancer; Cytological screening; HPV; Vaccination

Indexed keywords

VIRUS DNA; WART VIRUS VACCINE;

ADULT; ARTICLE; CANCER INVASION; CANCER SCREENING; CONTROLLED STUDY; CYTOLOGY; ENZYME IMMUNOASSAY; FEMALE; GENOTYPE; HISTOPATHOLOGY; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; MAJOR CLINICAL STUDY; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; UNITED KINGDOM; UTERINE CERVIX CANCER; VERRUCA VULGARIS; VIRUS TYPING;

ADENOCARCINOMA; ADOLESCENT; CARCINOMA, SQUAMOUS CELL; DNA, VIRAL; FEMALE; HUMAN PAPILLOMAVIRUS 16; HUMAN PAPILLOMAVIRUS 18; HUMANS; MASS SCREENING; NEOPLASM INVASIVENESS; NEOPLASM STAGING; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; POLYMERASE CHAIN REACTION; PROGNOSIS; RETROSPECTIVE STUDIES; RISK FACTORS; UTERINE CERVICAL NEOPLASMS; WALES;

EID: 70349871223     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.24571     Document Type: Article

References (17)

1. Harper DM, Franco EL, Wheeler CM, Moscicki AB, Romanowski B, Roteli-Martins CM, Jenkins D, Schuind A, Costa Clemens SA, Dubin G. Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial. Lancet 2006;367:1247-1255
2. Munoz N, Bosch FX, Castellsague X, Diaz M, de Sanjose S, Hammouda D, Shah KV, Meijer CJ. Against which human papillomavirus types shall we vaccinate and screen? The international perspective. Int J Cancer 2004;111:278-285 (Pubitemid 38924707)
3. Smith JS, Lindsay L, Hoots B, Keys J, Franceschi S, Winer R, Clifford GM. Human papillomavirus type distribution in invasive cervical cancer and high-grade cervical lesions: a meta-analysis update. Int J Cancer 2007;121:621-632 (Pubitemid 46986496)
4. Gilbert MT, Haselkorn T, Bunce M, Sanchez JJ, Lucas SB, Jewell LD, Van Marck E, Worobey M. The isolation of nucleic acids from fixed, paraffin-embedded tissues-which methods are useful when? PLoS ONE 2007;2:e537.
5. Jacobs MV, Snijders PJ, van den Brule AJ, Helmerhorst TJ, Meijer CJ, Walboomers JM. A general primer GP5+/GP6(+)-mediated PCR-enzyme immunoassay method for rapid detection of 14 high-risk and 6 low-risk human papillomavirus genotypes in cervical scrapings. J Clin Microbiol 1997;35:791-795
6. Hibbitts S, Rieck GC, Hart KW, Powell NG, Beukenholdt R, Dallimore N, McCrea J, Hauke A, Tristram A, Fiander N. Human papillomavirus infection-an anonymous prevalence study in South Wales, UK. Br J Cancer 2006;95:226-232 (Pubitemid 44050922)
7. Qu W, Jiang G, Cruz Y, Chang CJ, Ho GY, Klein RS, Burk RD. PCR detection of human papillomavirus: comparison between MY09/MY11 and GP51/GP61 primer systems. J Clin Microbiol 1997;35: 1304-1310 (Pubitemid 27216785)
8. Bosch FX, Manos MM, Munoz N, Sherman M, Jansen AM, Peto J, Schiffman MH, Moreno V, Kurman R, Shah KV. Prevalence of human papillomavirus in cervical cancer: a worldwide perspective. International biological study on cervical cancer (IBSCC) Study Group. J Natl Cancer Inst 1995;87:796-802.
9. Clifford GM, Smith JS, Plummer M, Munoz N, Franceschi S. Human papillomavirus types in invasive cervical cancer worldwide: a meta-analysis. Br J Cancer 2003;88:63-73.
10. Sasieni PD, Cuzick J, Lynch-Farmery E. Estimating the efficacy of screening by auditing smear histories of women with and without cervical cancer. The National Co-ordinating Network for Cervical Screening Working Group. Br J Cancer 1996;73:1001-1005
11. Im SS, Wilczynski SP, Burger RA, Monk BJ. Early stage cervical cancers containing human papillomavirus type 18 DNA have more nodal metastasis and deeper stromal invasion. Clin Cancer Res 2003;9:4145-4150
12. Schiffman M, Herrero R, Desalle R, Hildesheim A, Wacholder S, Rodriguez AC, Bratti MC, Sherman ME, Morales J, Guillen D, Alfaro M, Hutchinson M, et al. The carcinogenicity of human papillomavirus types reflects viral evolution. Virology 2005;337:76-84. (Pubitemid 40725441)
13. Woodman CB, Collins S, Rollason TP, Winter H, Bailey A, Yates M, Young LS. Human papillomavirus type 18 and rapidly progressing cervical intraepithelial neoplasia. Lancet 2003;361:40-43 (Pubitemid 36050960)
14. Krane JF, Granter SR, Trask CE, Hogan CL, Lee KR. Papanicolaou smear sensitivity for the detection of adenocarcinoma of the cervix: a study of 49 cases. Cancer 2001;93:8-15.
15. Bulk S, Visser O, Rozendaal L, Verheijen RH, Meijer CJ. Cervical cancer in The Netherlands 1989-1998: decrease of squamous cell carcinoma in older women, increase of adenocarcinoma in younger women. Int J Cancer 2005;113:1005-1009
16. Bray F, Carstensen B, Moller H, Zappa M, Zakelj MP, Lawrence G, Hakama M, Weiderpass E. Incidence trends of adenocarcinoma of the cervix in 13 European countries. Cancer Epidemiol Biomarkers Prev 2005;14:2191-2199 (Pubitemid 41603267)
17. Clifford GM, Gallus S, Herrero R, Munoz N, Snijders PJ, Vaccarella S, Anh PT, Ferreccio C, Hieu NT, Matos E, Molano M, Rajkumar R, et al. Worldwide distribution of human papillomavirus types in cytologically normal women in the International Agency for Research on Cancer HPV prevalence surveys: a pooled analysis. Lancet 2005; 366:991-998 (Pubitemid 41323035)